FLT3 and acute myeloid leukemia: Further development and investigation into TAM inhibitors is ongoing and include extensive development in biologic inhibitors, such as mAbs, though these have mostly been investigated in solid tumors.159 The combinational use of TAM inhibitors with current cytotoxic therapies and the dual inhibition of TAM and FLT3 pathways to combat therapeutic resistance in AML are promising and offer a way to expand current treatment options.